Abstract: A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX1CNLPVKPGPCX2GFFSAFYYSQKX3NKCHSFTYGGCAGNANRFSTX4EKCRRTC X5X6, wherein, X1 is the amino acid residue F or G, X2 is any amino acid residue, except a basic amino acid residue, X3 is the amino acid residue T or D, X4 is the amino acid residue I, L, or E, (i) X5 is V and X6 is G or (ii) X5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.

Abstract: The invention relates to adalimumab variants with reduced immunogenic potential and retained or increased affinity and therapeutic applications thereof.

Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising: the culturing, in a liquid medium, of at least one cell in a culture chamber, at least one wall of which comprises at least one sensitive area, a sensitive area comprising a plurality of ligands, attached to a solid support, each ligand being able to bind specifically to the compound, and an element for real-time transduction of a signal produced by the binding of the compound to one of the ligands; the identification, in a sensitive area, of at least one spot producing a signal; the real-time measurement of the signal produced by the spot identified, representing the amount of compound secreted by an individual cell.

Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

Abstract: The present invention concerns CD4+ T survivin epitopes and their vaccines and diagnostic uses.

Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

Abstract: The present invention concerns CD4+ T survivin epitopes and their vaccines and diagnostic uses.

Abstract: The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.

Abstract: The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.

Abstract: The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising: the culturing, in a liquid medium, of at least one cell in a culture chamber, at least one wall of which comprises at least one sensitive area, a sensitive area comprising a plurality of ligands, attached to a solid support, each ligand being able to bind specifically to the compound, and an element for real-time transduction of a signal produced by the binding of the compound to one of the ligands; the identification, in a sensitive area, of at least one spot producing a signal; the real-time measurement of the signal produced by the spot identified, representing the amount of compound secreted by an individual cell.

Abstract: The invention relates to a method for evaluating the immunogenicity of proteins in humans or animals, comprising analysing the CD4+ T lymphocyte response specific to the protein to be tested in individuals of the (human or animal) species in which the immunogenicity of said cell is analysed.

Abstract: A peptide derived from the Midkine protein, comprising at least one CD4+ T or CD8+ T epitope restricted by the HLA molecules predominant in the Caucasian population, or a polynucleotide encoding said peptide, as an anticancer vaccine or as a reagent for immunomonitoring of the cellular response against Midkine over the course of a cancer or of an anticancer treatment.

Abstract: A method of selecting a test molecule that binds to HLA-DP4 by (i) incubating HLA-DP4 with the test molecule and a labeled peptide of formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 thereby forming respective complexes, wherein Z1 and Z2, which may be identical or different, are each either zero or from 1 to 100 amino acids; X1 is an aromatic or hydrophobic amino acid, or S; X6 is an aromatic or hydrophobic amino acid, or C; X9 is an aromatic or hydrophobic amino acid, or C, D, Q, S, T, or E; and X2, X3, X4, X5, X7 and X8 are each an amino acid; (ii) separating the respective complexes formed; (iii) detecting the HLA-DP4/labeled peptide complexes; and (iv) selecting the test molecule that exhibits a binding activity of IC50<1000 nM, which corresponds to the concentration of the test molecule that inhibits 50% of the competitive HLA-DP4 binding of the labeled peptide.

Abstract: The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine.

Abstract: A method of selecting a test molecule that binds to HLA-DP4 by (i) incubating HLA-DP4 with the test molecule and a labeled peptide of formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 thereby forming respective complexes, wherein Z1 and Z2, which may be identical or different, are each either zero or from 1 to 100 amino acids; X1 is an aromatic or hydrophobic amino acid, or S; X6 is an aromatic or hydrophobic amino acid, or C; X9 is an aromatic or hydrophobic amino acid, or C, D, Q, S, T, or E; and X2, X3, X4, X5, X7and X8 are each an amino acid; (ii) separating the respective complexes formed; (iii) detecting the HLA-DP4/labeled peptide complexes; and (iv) selecting the test molecule that exhibits a binding activity of IC50<1000 nM, which corresponds to the concentration of the test molecule that inhibits 50% of the competitive HLA-DP4 binding of the labeled peptide.

Abstract: The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same.

Abstract: The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine.